

1 **cAMP prevents antibody-mediated thrombus formation in COVID-19**

2

3 Jan Zlamal^{1*}, Karina Althaus^{1,2*}, Hisham Jaffal¹, Lisann Pelzl¹, Anurag Singh¹, Andreas

4 Witzemann¹, Helene Häberle³, Valbona Mirakaj³, Peter Rosenberger³ and Tamam

5 Bakchoul^{1,2}

6

7 ¹Institute for Clinical and Experimental Transfusion Medicine, Medical Faculty of Tuebingen,
8 University Hospital of Tuebingen

9 ²Centre for Clinical Transfusion Medicine, University Hospital of Tuebingen

10 ³Department of Anesthesiology and Intensive Care Medicine, University Hospital of
11 Tuebingen

12 * Indicates equal contribution

13

14 Running title: cAMP prevents antibody-induced procoagulant platelets

15 Tables: 1

16 Figures: 10

17

18 **Key words:** procoagulant platelet, Fc-gamma-receptor IIA, COVID-19, cAMP

19

20 **Corresponding author:**

21 Tamam Bakchoul , MD

22 University Hospital of Tuebingen

23 Otfried-Müller-Straße 4/1

24 72076 Tübingen

25 Tel: +49-(0)7071 / 29-81601, Fax: +49-(0)7071 / 29-5240

26 E-mail: tamam.bakchoul@med.uni-tuebingen.de

27

28

29

30 **Key points**

- 31 - Fc-gamma-receptor IIA mediated PS externalization on the PLT surface
32 triggers increased thrombus formation
33 - Inductors of cAMP inhibit antibody-mediated thrombus formation and may
34 have potential therapeutic advantage in COVID-19

35

36 **Abstract**

37 Thromboembolic events are frequently reported in patients infected with the SARS-
38 CoV-2 virus. However, the exact mechanisms of thromboembolic events remain
39 elusive. In this work, we show that immunoglobulin G (IgG) subclass in patients with
40 COVID-19 trigger the formation of procoagulant PLTs in a Fc-gamma-RIIA (FcγRIIA)
41 dependent pathway leading to increased thrombus formation in vitro. Most
42 importantly, these events were significantly inhibited via FcγRIIA blockade as well as
43 by the elevation of PLTs' intracellular cyclic-adenosine-monophosphate (cAMP)
44 levels by the clinical used agent Iloprost. The novel findings of FcγRIIA mediated
45 prothrombotic conditions in terms of procoagulant PLTs leading to higher thrombus
46 formation as well as the successful inhibition of these events via Iloprost could be
47 promising for the future treatment of the complex coagulopathy observed in COVID-
48 19 disease.
49

50 **Introduction**

51 Infection with SARS-CoV-2 has been shown to be associated with abnormalities in
52 the coagulation system with an increased incidence of thromboembolic events in
53 small vessels leading to higher mortality (1-3). Accumulating evidence suggests
54 upregulated release of inflammatory cytokines and increased interaction between
55 different actors of innate and adaptive immunity as the main causes for the
56 prothrombotic environment observed in COVID-19 disease (4). Moreover, a
57 significant number of reports described platelet (PLT) hyperactivity in patients with
58 COVID-19, which is assumed to contribute to prothrombotic conditions (5, 6).
59 Procoagulant PLTs, predominantly generated at the outer side of the growing
60 thrombus, are increasingly recognized to link primary with secondary haemostasis (7-
61 10). The latter is mainly executed by negatively charged membrane phospholipids
62 externalized on the PLT surface. This unique feature of procoagulant PLTs enables
63 the assembly of tenase as well as prothrombinase complexes leading to high
64 thrombin burst, increased fibrin deposition and thrombus formation (11). Recently, we
65 showed that PLTs from patients with severe COVID-19 infection express a
66 procoagulant phenotype. Immunoglobulin G (IgG) fractions were found to be
67 responsible for the COVID-19 induced procoagulant PLTs (Althaus et al. accepted).

68 In the current study, we investigate the time course of the generation of
69 antibody- induced procoagulant PLTs as well as the mechanisms leading to
70 alterations in the PLT phenotype in COVID-19. We observed that IgG fractions from
71 severe COVID-19 patients induce increased thrombus formation in an Fc-gamma
72 RIIA (FcγRIIA) dependent manner. More importantly, we were able to show that
73 cyclic-adenosine-monophosphate (cAMP) elevation in PLTs prevents COVID-19
74 antibody-induced procoagulant PLT generation as well as clot formation.

75 **Materials and Methods**

76 ***Patients and sera***

77 Experiments were performed using leftover serum material from COVID-19 patients
78 who were referred to our laboratory between March and June 2020. The diagnosis of
79 SARS-CoV-2 infection was confirmed by real time PCR on material collected by
80 nasal swabs. Sera from ICU non-Covid-19 patients with postoperative sepsis were
81 collected to serve as ICU control group. Additionally, sera were collected from
82 healthy blood donors at the Blood Donation Centre Tuebingen after written
83 consensus was obtained to establish cutoff values when appropriate. Serum samples
84 were stored at -80°C and thawed at room temperature prior to the performed
85 experimental procedure. All sera were heat-inactivated at 56°C for 30 minutes (min),
86 which was followed by a centrifugation step at 5000xg. The spun-down was
87 discarded and supernatants were handled as described in the following sections.

88 ***IgG preparation***

89 IgG fractions were isolated by the use of a commercially available IgG-purification-kit
90 (MelonTM-Gel IgG Spin Purification Kit, Thermo Fisher Scientific, Waltham, USA) and
91 used as recommended by the manufacturer. In brief, heat inactivated serum was
92 diluted 1:10 in purification buffer and incubated with the kit specific Gel IgG
93 Purification Support over four cycles for 10 min. Subsequently, periodically performed
94 centrifugation steps through a 10 µm pore size filter tube were performed for 1 min at
95 5000xg. The flow throw was collected into 100 kDa-pore sized centrifugal filters
96 (Amicon Ultra-4, Merck Millipore, Cork, Ireland) with subsequent concentration to the
97 initial volume of the used serum sample via centrifugation (10-15 min, 2000xg, 4°C,
98 with brake). Afterwards, IgG concentrations were measured at a mass extinction

99 coefficient of 13.7 at 280 nm wavelength using a NanoDrop One spectrophotometer
100 (VWR, Bruchsal, Germany). IgG purity was verified using Coomassie staining
101 (Abcam, Cambridge, UK).

102 ***Preparation of washed platelets***

103 Washed platelets (wPLTs) were prepared from venous blood samples as described
104 previously (12). Briefly, whole blood from healthy donors was withdrawn by cubital
105 venipuncture into acidic-dextrose containing vacutainers (Becton-Dickinson,
106 Plymouth, UK) and allowed to rest for 45 min at 37°C. After centrifugation (20 min,
107 120xg, room temperature [RT], no brake) PLT-rich-plasma (PRP) was gently
108 separated and supplemented with apyrase (5 µL/mL, Sigma-Aldrich, St. Louis, USA)
109 and prewarmed ACD-A (111 µL/mL, Terumo BCT, Inc., Lakewood, USA). After an
110 additional centrifugation step (7 min, 650xg, RT, no brake), the PLT pellet was
111 resuspended in 5 mL of wash-solution (modified Tyrode buffer: 5 mL bicarbonate
112 buffer, 20 percent (%) bovine serum albumin, 10% glucose solution [Braun,
113 Melsungen, Germany], 2.5 U/mL apyrase, 1 U/mL hirudin [Pentapharm, Basel,
114 Swiss], pH 6.3) and allowed to rest for 15 min at 37°C. Following final centrifugation
115 (7 min, 650xg, RT, no brake) wPLTs were resuspended in 2 mL of resuspension-
116 buffer (50 mL of modified Tyrode buffer, 0.5 mL of 0.1 M MgCl₂, 1 mL of 0.2 M
117 CaCl₂, pH 7.2) and adjusted to 300x10⁹ PLTs/L after the measurement at a Cell-Dyn
118 Ruby hematological analyzer (Abott, Wiesbaden, Germany) was performed. For
119 calcium chelation experiments, the PLT pellet was resuspended with resuspension-
120 buffer without the supplementation of calcium (50 mL of modified Tyrode buffer, 0.5
121 mL of 0.1 M MgCl₂, pH 7.2).

122 ***Treatment of wPLTs with ICU COVID-19 sera/IgG***

123 wPLTs (7.5×10^6) were supplemented with 5 μ L serum/IgG from ICU COVID-19
124 patients or control serum/IgG and incubated for 1.5 hours (hs) at RT under rotating
125 conditions. Afterwards, samples were washed once (7 min, 650xg, RT, no brake),
126 resuspended in 100 μ L of phosphate buffered saline (PBS, [Biochrom, Berlin,
127 Germany]) and further handled as described in the following sections.

128 ***Detection of phosphatidylserine exposure***

129 To assess externalization of phosphatidylserine (PS) on the PLT surface after
130 antibody treatment, 10 μ L of PLT suspension were transferred into 100 μ L of Hank's
131 balanced salt solution (HBSS), (137 mM NaCl, 1.25 mM CaCl₂, 5.5 mM glucose,
132 [Carl-Roth, Karlsruhe, Germany]) and incubated with 1 μ L Annexin V-FITC
133 (Immunotools, Friesoythe, Germany) for 30 min at RT in the dark. To induce the
134 maximal externalization of PS on the PLT surface, wPLTs were incubated with
135 ionomycin (Sigma-Aldrich, St. Louis, USA, [5 μ M, 15 min at RT]). Afterwards, PLTs
136 were filled up with HBSS to a final volume of 500 μ L and acquired at a flow cytometer
137 ([FC], Navios, Beckman-Coulter, Brea, USA).

138 PLTs were gated based on their characteristic forward scatter (FSC) vs. side
139 scatter (SSC) properties as well as CD41a and CD42a expression (anti-CD41a-PC5
140 and anti-CD42a-PerCP, both BD, San Jose, USA), respectively. Test results were
141 analyzed as fold increase of the percentage PS positive PLTs compared to PLTs that
142 were incubated with serum/IgG from healthy individuals.

143 ***Determination of changes in the inner-mitochondrial-transmembrane potential*** 144 ***($\Delta\Psi$)***

145 Changes of the mitochondrial inner transmembrane potential ($\Delta\Psi$) induced by ICU
146 COVID-19 sera/IgG were analyzed by FC, as previously reported (13). Briefly, after

147 treatment with IgG/serum from ICU COVID-19 patients, wPLTs ($\sim 2 \times 10^6$) were
148 incubated with a final concentration of 10 μM tetramethylrhodamine, ethyl ester
149 (TMRE, Abcam, Cambridge, UK) for 30 min at RT in the dark. Carbonyl cyanide 4-
150 (trifluoromethoxy) phenylhydrazone (FCCP, Abcam, Cambridge, UK) which is an
151 uncoupler of mitochondrial oxidative phosphorylation served as positive control in
152 each experiment. After staining with TMRE, PLTs were filled up with PBS to a final
153 volume of 500 μL and immediately analyzed by FC. Changes in the $\Delta\Psi$ were
154 determined in gated PLTs as percentage of TMRE negative events and normalized to
155 PLTs that were treated with serum/IgG from healthy controls.

156 ***Phenotyping of different PLT-populations***

157 ICU COVID-19 serum/IgG-mediated procoagulant changes (PS/CD62p-double
158 positive) were assessed in some experiments using a triple staining. Briefly, 10 μL
159 ($\sim 1 \times 10^6$) of the resuspended PLT suspension were transferred into 10 μL of HBSS
160 and incubated with 1 μL anti-CD62p-APC (BD, San Jose, USA), 1 μL Annexin-FITC
161 (Immunotools, Friesoythe, Germany) and 1 μL anti-CD42a-PerCP (BD, San Jose,
162 USA) for 15 min at RT in the dark. PLTs treated with thrombin receptor activating
163 peptide (TRAP-6, [20 μM , 30 min at RT]) and ionomycin (5 μM , 15 min at RT, [both
164 Sigma-Aldrich, St. Louis, USA]) served as positive controls. Afterwards, PLTs were
165 resuspended with HBSS to a final volume of 500 μL and immediately assessed via
166 FC. In selected experiments that were designed to investigate the impact of calcium
167 on cell signalling, PLT PS externalization was assessed by the use of the calcium
168 independent marker lactadherin. 1 μL of lactadherin-FITC (Haematologic
169 Technologies, Essex Junction, USA) was incubated with wPLTs as for Annexin-FITC
170 for 15 min at RT, in the dark, and the PLT suspension filled up to final volume of 500
171 μL with PBS prior to FC analysis.

172 ***Western blot analysis of caspase 3 cleavage***

173 Protein levels of cleaved-caspase 3 were determined by western blot. After
174 serum/IgG incubation, cells were washed with PBS for 7 min, 700xg at 4°C.
175 Subsequently, the pellet was resuspended in 100 µL of ice-cold RIPA lysis buffer
176 containing HALT™ protease and phosphatase inhibitor-cocktail (both ThermoFisher
177 Scientific, Paisley, UK). Protein concentrations were determined using the NanoDrop
178 One spectrophotometer (VWR, Bruchsal, Germany). 100 µg of protein was
179 solubilized in sample buffer (Invitrogen™, Carlsbad, USA) at 95°C for 10 min.
180 Proteins were separated by electrophoresis using 12% SDS-PAGE gels in glycine-
181 tris buffer. Thereafter, probes were transferred to polyvinylidene difluoride (PVDF)
182 membranes (0.45 µm, Merck, Tullagreen, Ireland). Afterwards, membranes were
183 blocked with 5% milk in tris-buffered saline (TBS-T, 20 mM Tris, 140 mM NaCl, 0.1%
184 Tween, pH 7.6) at RT for 1 h. Membranes were then incubated with primary anti-
185 human cleaved-caspase 3 antibody (1:1000, Abcam, Cambridge, UK) and anti-
186 human alpha-tubulin (1:1000, Cell Signaling Technology, Danvers, USA) at 4°C
187 overnight. After washing with TBS-T buffer, the membranes were incubated with the
188 appropriate secondary anti-rabbit or anti-mouse antibody conjugated with IRDye®680
189 / IRDye®800 (1:3000, LI-COR®, Lincoln, USA) for 1 h at RT. Protein bands were
190 detected after additional washes (TBS-T) with Odyssey infrared imaging system (LI-
191 COR®, Lincoln, USA). Western blots were analyzed by ImageJ software (NIH,
192 Bethesda, USA). The results are shown as the ratio of total cleaved-caspase 3 to
193 procaspase 3 (full fragment) and normalized to wPLTs that were treated with healthy
194 control serum/IgG.

195 ***Assessment of the mechanisms of antibody-mediated effects on PLTs***

196 75 μ L wPLTs were pretreated with the Fc γ RIIA blocking monoclonal antibody (moAb)
197 anti-CD32 (5 μ L moAb IV.3; stemcell™ technologies, Vancouver, Canada) for 45 min
198 at 37°C prior to serum/IgG treatment. A monoclonal isotype (moAb) served as
199 vehicle control ([SC-2025], Santa Cruz Biotechnology, Dallas, USA).

200 For the chelation of extracellular calcium, the non-membrane permeable
201 chelator of extracellular calcium EGTA (Ethyleneglycol-bis(2-aminoethylether)-
202 N,N,N',N'-tetraacetic acid, 1 mM, 5 min at 37°C [Sigma Aldrich, St. Louis, USA]) was
203 used.

204 For the depletion of calcium in the inner compartment of PLTs, the intracellular
205 chelator of calcium BAPTA-AM (1,2-Bis(2-aminophenoxy)ethane-N,N,N',N'-
206 tetraacetic acid tetrakis(acetoxymethyl) ester, 20 μ M, 15 min at 37°C, [Selleck,
207 Houston, USA]) was used.

208 To investigate the effect of increased intracellular levels of cAMP, wPLTs were
209 pretreated with the adenylate cyclase (ADC) inducers Forskolin (2.25 μ M) and
210 Iloprost (20 nM, both Sigma-Aldrich, St. Louis, USA) prior to the incubation with
211 sera/IgGs from ICU COVID-19 patients.

212 ***Investigations of antibody-mediated thrombus formation***

213 To assess the impact of ICU COVID-19 IgG-induced effects on clot formation, an ex
214 vivo model for thrombus formation was established. A microfluidic system (BioFlux,
215 Fluxion Biosciences, Alameda, USA) was used at a shear rate of 1500⁻¹ (60 dyne)
216 according to the recommendations of the ISTH standardization committee for
217 biorheology (14). Briefly, microfluidic channels were coated with collagen (100
218 μ g/mL, Collagen Horm, Takeda, Linz, Austria) overnight at 4°C and blocked with

219 2.5% of human serum albumin (HSA, Kedrion, Barga, Italy) 1 h before perfusion at
220 RT.
221 Whole blood samples of healthy individuals of blood group O were collected into
222 hirudin containing monovettes (Sarstedt, Nuembrecht, Germany) and allowed to rest
223 for 30 min at RT. After splitting the whole blood into aliquots of 200 μ L, PRP was
224 prepared via centrifugation (20 min, 120xg, at RT, no break). Afterwards, 45 μ L of the
225 supernatant PRP was gently separated and incubated with 5 μ L of control or ICU
226 COVID-19 IgG fractions and incubated for 90 min at RT under rotating conditions. 15
227 min prior to the end of the incubation period, Calcein-FITC (4 μ M, [Thermo Scientific,
228 Eugene, Oregon, USA]) was added to each sample. Subsequently, PRP was gently
229 added back to reconstitute whole blood samples.

230 When indicated, the separated PRP was pretreated with moAb IV.3 or moAb
231 isotype control at a concentration of 20 μ g/mL for 30 min at RT. For cAMP induction,
232 PRP was pretreated with Iloprost (20 nM) or vehicle control (5 min, 37°C) prior to IgG
233 incubation.

234 Finally, reconstituted whole blood samples were run at a shear rate of 1500s⁻¹
235 (60 dyne) for a maximum of 5 min. Immunofluorescence and bright field images were
236 taken from 3-5 randomly chosen microscopic fields (x20, Olympus IX73, Olympus
237 GmbH, Hamburg, Germany). Clot formation was assessed by measuring the % of
238 surface area coated by thrombus (SAC) of 3-5 images via ImageJ (NIH, Bethesda,
239 USA) and normalized to the whole area.

240 **Statistical analysis**

241 Statistical analyses were performed using GraphPad Prism 7 (La Jolla, USA). T-test
242 was used to analyze normally distributed results. Non-parametric test (Mann-Whitney
243 test) was used when data failed to follow a normal distribution as assessed by

244 D'Agostino and Pearson omnibus normality test. Group comparison was performed
245 using the Wilcoxon rank-sum test and the Fisher exact test with categorical variables.
246 A p-value <0.05 was assumed to represent statistical significance.

247 ***Ethics***

248 Studies involving human material were approved by the Ethics Committee of the
249 Medical Faculty, Eberhard-Karls University of Tuebingen, Germany, and were
250 conducted in accordance with the declaration of Helsinki.

251 **Results**

252 ***Patient characteristics***

253 Sera from 26 ICU COVID-19 patients were enrolled in this study between March the
254 1st and June the 16th 2020. 21 of these ICU COVID-19 patients were included in a
255 previous study (Althaus et al. accepted). The mean age of ICU COVID-19 patients
256 was 58 years (range: 29-88 years). 20/30 (67%) patients had known risk factors for
257 severe COVID-19 infection as described previously (15), including hypertension
258 18/30 (60%), obesity 6/30 (20%), coronary artery disease 4/30 (13%) and diabetes
259 mellitus 6/30 (20%). Elevated D-Dimer levels were detected in all patients (median,
260 range: 3.4 mg/dL, 0.9-45.0 mg/dL) and thrombosis was diagnosed in 13/30 (43%)
261 patients. Longitudinal blood samples were available from four COVID-19 patients
262 who were first admitted to normal ward and later to the ICU for mechanical
263 ventilation. As ICU control group, 5 patients who were admitted to ICU due to non-
264 COVID-19 related causes were included in this study.

265 ***Sera from ICU COVID-19 patients induce progressive increase of procoagulant*** 266 ***PLTs***

267 To investigate whether sera of ICU COVID-19 patients have the potential to induce
268 an increased $\Delta\psi$ depolarization as well as PS externalization on the PLT surface,
269 wPLTs from healthy individuals were incubated with sera from 26 ICU COVID-19
270 patients with a severe course of disease as well as 5 ICU non-COVID-19 patients.
271 Based on the calculated cutoffs (mean+2xSD of healthy controls), 19/26 (73%) sera
272 from patients with severe COVID-19 disease induced significantly higher $\Delta\psi$
273 depolarization in PLTs from healthy donors compared to ICU controls (FI in % $\Delta\psi$
274 depolarization \pm SEM: 6.10 \pm 1.12 vs. 0.67 \pm 0.10, p value <0.0001, Fig. 1 A). In addition,

275 significantly higher PS externalization was observed when ICU COVID-19 sera were
276 incubated with PLTs compared to ICU control sera (FI in % PS \pm SEM: 2.12 \pm 0.19 vs.
277 1.12 \pm 0.08, p value <0.0001, Fig. 1 B).

278 Next, we sought to investigate the time course of the observed changes in
279 both markers. Longitudinal blood samples were available from four ICU COVID-19
280 patients. Sera were collected at hospital admission (normal ward or ICU) and during
281 a follow up period at ICU for up to 14 days. As shown in Fig. 1 C-F, sera from ICU
282 COVID-19 patients induced significant changes in $\Delta\psi$ depolarization, PS
283 externalization and caspase 3 cleavage as clinical manifestation worsen requiring
284 admission to ICU. Of note, antibody-induced changes peaked within day 3 and 7 of
285 the ICU stay (FI in % $\Delta\psi$ depolarization \pm SEM: 3.71 \pm 0.72, p value 0.0070; and % PS
286 externalization \pm SEM: 4.80 \pm 1.11, p value <0.0001, respectively, Suppl. Fig. 1).

287 These findings were further supported by WB analyses, as PLTs incubated with the
288 corresponding ICU COVID-19 serum induced caspase 3 cleavage in similar kinetic
289 (Ratio of cleaved caspase 3/procaspase 3 normalized to control \pm SEM: 4.84 \pm 0.45, p
290 value 0.0035, Fig. 1 E+F). Notably, the rise of PLT markers was associated with
291 increasing levels of detected IgGs against the spike S protein of SARS-CoV-2 in the
292 corresponding ICU COVID-19 patients' follow up sera but not in the total IgG
293 contents of isolated IgG fractions (Suppl. Fig. 2 A and B, respectively). Moreover,
294 declining PLT-counts were observed as $\Delta\psi$ depolarization as well as PS
295 externalization increased, vice versa (Suppl. Fig. 3 A and B, respectively).

296 ***IgGs from severe COVID-19 trigger procoagulant PLTs with increased ability to***
297 ***form blood clots***

298 To further verify the impact of sera from severe COVID-19 patients on PLTs, the
299 expression of the alpha granule release and PLT activation marker CD62p was

300 analyzed in two colour FC in parallel to PS. FC analyses revealed that IgG fractions
301 from severe COVID-19 patients induce remarkable changes in the PLT SSC and
302 FSC (Fig. 2.1. A+C), as well as in the distribution of CD62p/PS positivity (Fig. 2.1.
303 B+D). In contrast, the PLT population was almost non-affected after incubation with
304 IgGs from healthy controls (HCs) or ICU non-COVID-19 control patients. Overall,
305 higher percentage of double positive events was observed after incubation with IgGs
306 from ICU COVID-19 patients compared to ICU and to HCs (% CD62p/PS positive
307 PLTs \pm SEM: 31.63 \pm 3.86 vs. 4.04 \pm 1.16, p value 0.0007; and vs. 2.88 \pm 0.52, p value
308 <0.0001, respectively, Fig. 2.1. II.). Additionally, significant elevation was observed in
309 the PS single positive PLT population (% PS positive PLTs \pm SEM: 13.17 \pm 2.05 vs.
310 2.66 \pm 0.52, p value <0.0001; and vs. 2.36 \pm 0.29, p value 0.0002, Fig. 2.1. I) but not in
311 the percentage of CD62p single positive PLTs (% CD62p positive PLTs \pm SEM:
312 19.40 \pm 1.83 vs. 13.53 \pm 1.90, p value 0.1011, Fig. 2.1. III).

313 Next, we sought to investigate the ability of IgG fractions from patients with
314 severe COVID-19 to cause increased clot formation. PLTs from healthy individuals
315 were incubated with IgGs from ICU COVID-19 patients or ICU and HCs, added to
316 autologous whole blood samples and finally perfused through collagen covered
317 microfluidic channels at a shear rate of 1500 s⁻¹ (60 dyne). As shown in Fig. 3 A, IgG
318 from severe COVID-19 patients caused increased clot formation. Overall, significantly
319 higher surface area coverage by thrombus (SAC) was observed in the presence of
320 ICU COVID-19 IgGs compared to ICU controls and HCs (mean % SAC \pm SEM:
321 13.95% \pm 1.55 vs. 2.86 \pm 1.10, p value 0.0070; and vs. 2.70 \pm 0.83, p value 0.0002,
322 respectively, Fig. 3 B). Together with the increased percentage of procoagulant PLTs
323 (CD62p/PS positive) in response to ICU COVID-19 IgGs, these findings might
324 provide a potential explanation for the increased thromboembolic events in severely
325 affected COVID-19 patients.

326 ***ICU COVID-19 IgGs cause procoagulant PLTs via crosslinking FcγRIIA***

327 To further determine the underlying mechanistic pathways leading to ICU COVID-19
328 IgG induced formation of procoagulant PLTs, we next considered a potential ligation
329 of FcγRIIA by patients' sera/IgGs. For this purpose, wPLTs were pretreated with the
330 moAb IV.3. This FcγRIIA blockade resulted in marked inhibition of the antibody-
331 induced $\Delta\psi$ depolarization (FI in % $\Delta\psi$ depolarization \pm SEM: 5.51 \pm 0.94 vs.
332 1.18 \pm 0.08, p value 0.0020, Fig. 4.1. A) as well as significant reduction of caspase
333 activation (Ratio of cleaved caspase 3/procaspase 3 \pm SEM: 4.70 \pm 1.16 vs. 1.33 \pm 0.29,
334 p value 0.0286, Fig. 4.1. B+C). Intriguingly, the blockade of FcγRIIA almost abolished
335 the changes in PLTs' FSC and SSC properties (Fig. 4.2. A+C), and markedly
336 reduced CD62p/PS double positive PLT population compared to isotype-control (%
337 CD62p/PS positive PLTs \pm SEM: 48.91 \pm 3.05 vs. 12.88 \pm 1.65, p value 0.0078, Fig. 4.2.
338 II).

339 Next, we analyzed the impact of FcγRIIA blockade on antibody-mediated clot
340 formation. Pretreatment of PLTs with moAb IV.3 prior to ICU COVID-19 IgG
341 incubation resulted in significant reduction of clot formation compared to isotype-
342 control (mean % SAC \pm SEM: 16.49 \pm 1.02 vs. 5.84 \pm 1.93, respectively, p value 0.0090,
343 Fig. 5 A+B). These results indicate that ICU COVID-19 IgG antibodies that are
344 present in a subgroup of severe ICU COVID-19 patients have the capability to induce
345 formation of procoagulant PLTs with increased clotting ability via crosslinking
346 FcγRIIA.

347 ***Calcium is pivotal for the generation of ICU COVID-19-IgG induced***
348 ***procoagulant PLTs***

349 Following the detection of an ICU COVID-19 IgG-induced procoagulant PLT
350 phenotype, we sought to investigate the underlying intracellular molecular
351 mechanisms. The contribution of calcium was analyzed by the depletion of extra- and
352 intracellular calcium contents via EGTA and BAPTA, respectively. Extracellular
353 calcium depletion caused significant inhibition of $\Delta\psi$ depolarization (FI in % $\Delta\psi$
354 depolarization \pm SEM: 3.08 \pm 0.18 vs. 1.94 \pm 0.20, p value 0.0079, Fig. 6.1. A) as well as
355 marked reduction of caspase 3 cleavage (Ratio of cleaved caspase 3/procaspase
356 3 \pm SEM: 4.14 \pm 0.65 vs. 1.50 \pm 0.20, p value 0.0079, Fig. 6.1. B+C). Moreover,
357 depletion of extracellular calcium significantly inhibited ICU COVID-19 IgG induced
358 alterations of wPLTs' morphology (Fig. 6.2. A-D) as well as the generation of
359 CD62p/PS positive PLTs (% CD62p/PS positive PLTs \pm SEM: 32.89 \pm 2.77 vs.
360 6.42 \pm 1.21, p value 0.0039, Fig. 6.2. II).

361 Similar effects were observed as depleting intracellular calcium stores. BAPTA
362 treatment resulted in significant inhibition of ICU COVID-19 IgG-induced $\Delta\psi$
363 depolarization (FI in % $\Delta\psi$ depolarization \pm SEM: 4.46 \pm 0.73 vs. 0.99 \pm 0.09, p value
364 0.0039, Fig. 7.1. A) and caspase 3 cleavage (Ratio of cleaved caspase 3/procaspase
365 3 \pm SEM: 3.50 \pm 0.98 vs. 0.43 \pm 0.06, p value 0.0286, respectively, Fig. 7.1. B+C). In
366 addition, BAPTA pretreatment of wPLTs resulted in marked prevention of ICU
367 COVID-19 IgG-induced changes in FSC and SSC (Figure 7.2. A-D as well as
368 significant reduction of CD62p/PS positive PLTs (% CD62p/PS positive PLTs:
369 29.58 \pm 3.36 vs. 1.74 \pm 0.39, p value 0.0020, Fig. 7.2. II).

370 ***Activation of cAMP protects against ICU COVID-19 IgG induced procoagulant*** 371 ***PLTs***

372 The interplay between the signalling pathways of the intracellular second
373 messengers, cAMP and calcium, has been shown to have an important role in

374 numerous essential physiological processes during PLT activation and apoptosis (16,
375 17). Therefore, we investigated the role of cAMP on COVID-19 antibody-induced
376 formation of procoagulant PLTs. Forskolin, an activator of intracellular ADC that
377 elevates intracellular levels of cAMP, was recently reported to inhibit the formation of
378 apoptotic PLTs in immune thrombocytopenia (18). The pretreatment of PLTs with
379 Forskolin led to significant reduction of ICU COVID-19 IgG-induced $\Delta\psi$ depolarization
380 (FI in % $\Delta\psi$ depolarization \pm SEM: 5.10 ± 0.70 vs. 1.43 ± 0.17 , p value 0.0079, Fig. 8.1.
381 A) and caspase 3 cleavage (Ratio of cleaved caspase 3/procaspase 3 \pm SEM:
382 3.74 ± 1.14 vs. 1.01 ± 0.14 , p value 0.0313, respectively, Fig. 8.1. B+C). In addition,
383 Forskolin pretreatment of wPLTs led to reduction of ICU COVID-19 IgG-induced
384 changes in FSC and SSC properties (Fig. 8.2. A-D) as well as to a significant
385 inhibition of procoagulant PLT generation (% CD62p/PS positive PLTs \pm SEM:
386 35.29 ± 1.58 vs. 12.26 ± 2.74 , p value 0.0313, Fig. 8.2. II). These findings indicate that
387 the elevation of intracellular cAMP prevents ICU COVID-19 IgG-induced formation of
388 procoagulant PLTs.

389 More importantly and of high clinical interest, similar protective effect was
390 observed with Iloprost, an already approved cAMP inducer (19). In fact, Iloprost
391 pretreatment of wPLTs led to marked reductions of ICU COVID-19 IgG-induced $\Delta\psi$
392 depolarization (FI of % $\Delta\psi$ depolarization \pm SEM: 4.66 ± 0.57 vs. 1.77 ± 0.32 , p value
393 0.0078, Fig. 9.1. A), and cleavage of caspase 3 (Ratio of cleaved caspase
394 3/procaspase 3 \pm SEM: 4.69 ± 1.45 vs. 2.0348 ± 0.38 , p value 0.0156, respectively, Fig.
395 9.1. B+C). In addition, Iloprost pretreatment led to a significant reduction of changes
396 in PLT morphology (Fig. 9.2. A-D) as well as in the number of procoagulant
397 CD62p/PS positive PLTs (% CD62p/PS positive PLTs \pm SEM: 41.36 ± 3.60 vs.
398 22.22 ± 3.92 , p value 0.0156, Fig. 9.2. II). Noteworthy, no significant changes were

399 observed in the number of CD62p single positive PLTs (% CD62p positive
400 PLTs \pm SEM: 24.48 \pm 2.2 vs. 26.51 \pm 3.94, p value 0.6875).

401 Based on these findings we were interested whether Iloprost might affect the
402 ability to form blood clots. Pretreatment of PLTs with Iloprost showed a marked
403 reduction in ICU COVID-19 IgG-induced clot formation compared to vehicle (mean %
404 SAC \pm SEM: 14.63 \pm 2.31 vs. 3.85 \pm 0.95, respectively, p value 0.0079, Fig. 10. A+B).
405 These findings provide the first evidence for a potential therapeutic use of Iloprost in
406 the treatment of the antibody-induced coagulopathy that is observed in COVID-19
407 disease.

408 **Discussion**

409 Our study showed that IgGs from patients with severe COVID-19 are able to induce
410 procoagulant PLTs with increased potential for clot formation via crosslinking FcγRIIA
411 in a calcium depending manner. Most importantly, we showed that cAMP activation
412 by an approved drug, namely Iloprost, can sufficiently inhibit the initiation of
413 procoagulant PLTs and the subsequent increased clot formation. These data may
414 have tremendous clinical implications.

415 Meanwhile, it is well established that COVID-19 infection is associated with
416 systemic prothrombotic state and increased incidence of thromboembolic
417 complications (20). However, the pre-sequelae events leading to the coagulopathy
418 observed in COVID-19 still remains elusive. Data from our study demonstrate the
419 presence of PLT-reactive IgG antibodies that harbour the ability to induce marked
420 changes in PLTs in terms of increased $\Delta\psi$ depolarization, PS externalization and P-
421 selectin expression, which are characteristic for procoagulant PLTs. A novel finding,
422 and potentially of high clinical interest, is that antibody-mediated formation of
423 procoagulant PLTs was associated with the clinical course as these changes
424 progressively increased as patients needed ventilation and peaked between day 3
425 and 7 on ICU. Probably, the kinetic of these markers might have predictive value to
426 monitor COVID-19-induced coagulopathy. In fact, PS externalization was recently
427 found to be a predictive biomarker for thromboembolic complications related to
428 cardiovascular therapeutic devices (21). In contrast to PS, conventional markers of
429 PLT activation were declared in this study to fail the detection of early activation
430 events leading to thrombosis.

431 The alterations in PLTs that were observed in our study after incubation with
432 sera from patients with severe COVID-19 infection, such as $\Delta\psi$ disruption, caspase 3

433 cleavage and PS externalization, could be found in apoptotic as well as procoagulant
434 PLTs. The involvement of PLT apoptosis to promote prothrombotic conditions has
435 been controversially discussed. In fact, recent data suggests that apoptotic PLTs are
436 unable to promote prothrombotic conditions (10). However, a clear dissection of the
437 molecular events leading to prothrombotic PLTs is challenging since activation of the
438 apoptosis caspase pathway has been described in the late phase of agonist-induced
439 PLT activation as well as in PLTs from patients with chronic kidney disease (22, 23),
440 which are prone to thromboembolic events. Our findings showed that antibody-
441 mediated $\Delta\psi$ disruption and caspase cleavage is associated with the induction of a
442 CD62p/PS positive PLT population suggesting that IgG antibodies in COVID-19
443 induce procoagulant rather than apoptotic PLTs. In fact, activated PLTs were shown
444 elsewhere to be predominant in COVID-19 patients (6). In particular, CD62p positive
445 PLTs were suggested to be involved in thrombosis in COVID-19 via the interaction
446 with neutrophil granulocytes leading to NET formation and increased interaction with
447 the inflamed vessel wall. Our data showed that COVID-19 IgG-antibodies trigger a
448 PLT population with procoagulant potential. An important finding that was reinforced
449 by data from an ex vivo microfluidic circulation system which revealed an increased
450 clot formation in the presence of COVID-19 IgG-antibodies.

451 Motivated by these novel functional data, we thought to dissect the exact
452 mechanistic pathways involved in the COVID-19 IgG-induced procoagulant status.
453 We found that ICU COVID-19 IgG-mediated changes in wPLTs involves the ligation
454 of the immune receptor Fc γ R1IA. The blockade of Fc γ R1IA significantly inhibits ICU
455 COVID-19 IgG-induced changes in $\Delta\psi$ depolarization as well as cleavage of caspase
456 3. Most importantly, Fc γ R1IA blockade reduced procoagulant CD62p/PS positive
457 PLTs and subsequently inhibited COVID-19 antibody-induced ex vivo clot formation.
458 While this findings are novel for COVID-19-associated coagulopathy, the correlation

459 between FcγRIIA ligation and increased risk for thromboembolic events is well
460 established for heparin-induced thrombocytopenia (HIT) (24). Interestingly, the IgG
461 antibody formation peaks in HIT within 5-10 day after exposure to heparin and is
462 associated with PLT consumption and increased risk for thrombosis (25). Similarly, in
463 our study the ability of ICU COVID-19 sera to induce procoagulant PLTs was most
464 pronounced between day 3 and 7. Of note, antibody-induced alterations in PLT
465 markers were accompanied by enhanced levels of IgG antibodies against the Spike
466 S epitope of SARS-CoV-2. These findings might suggest a transient onset of
467 misdirected autoimmune mechanisms that result in the emergence of PLT-reactive
468 antibodies leading to a prothrombotic status in severe COVID-19 infection.

469 Calcium is involved in many biological mechanistic pathways in PLTs (16). In
470 response to PLT agonists, calcium is released from the PLT internal stores which is
471 followed by amplifying second wave extracellular calcium influx via store (SOCE) and
472 receptor operated calcium entry (ROCE), respectively (26). The role of calcium
473 signalling in ITAM (immunoreceptor tyrosine-based activation motif) coupled GPVI
474 and (hem)ITAM coupled CLEC-2 receptor signalling has been well established in the
475 last few years (27). Additionally, FcγRIIA ligation has been shown to induce calcium
476 mobilization via ITAM signalling prior to platelet aggregation(28). In our study, the
477 depletion of calcium in the extracellular compartment inhibited ICU COVID-19 IgG-
478 induced procoagulant changes. This finding indicates that alterations in SOCE or
479 ROCE might be involved in the antibody-mediated generation of procoagulant PLTs
480 in COVID-19. In fact, the regulative role of SOCE for procoagulant PS externalization
481 has been previously reported, as SOCE channel inhibition resulted in reduced PS
482 externalization in human erythroleukemia cells (29). In addition, reduced PS
483 externalization and decreased clot formation was observed in chimeric mice that
484 express mutated impaired SOCE calcium channel Orai1 R93W on the PLT surface,

485 indicating that SOCE is a major inductor of PLT PS externalization and procoagulant
486 PLT formation (30). A potential role of ITAM-regulated signalling leading to
487 procoagulant PLTs has been also suggested. Calcium depletion inhibited GP VI
488 induced formation of procoagulant PLTs (31). In this study, the authors proposed that
489 distinct signalling cascades, most likely tyrosine and extracellular calcium dependent,
490 could be involved in the formation of procoagulant PLTs. Our findings emphasize the
491 role of extracellular calcium in FcγRIIA (ITAM) mediated procoagulant PLT formation.
492 Another possible explanation for these finding could be the loss of distinct calcium-
493 dependent conformational properties of PLT epitopes that are targeted by COVID-19
494 IgG antibodies. Dimeric PLT GP IIb/IIIa, the receptor for fibrinogen and well known
495 immunogenic epitopes of PLT-reactive autoantibodies in immune thrombocytopenia
496 (ITP), has been well characterized to be structurally dependent on extracellular
497 calcium levels (32). Although this might be currently too speculative, the depletion of
498 extracellular calcium might have inhibited antibody binding to such conformation-
499 sensitive epitopes on GP IIb/IIIa. ICU COVID-19 IgG-induced PLT alterations were
500 dependent on extracellular as well as intracellular calcium levels. Since PLT
501 apoptosis has been described to be independent of calcium (33), our finding
502 indicates that COVID-19 IgGs trigger FcγRIIA -mediated events that result in
503 procoagulant PLT formation in a calcium-dependent manner. In fact, similar findings
504 were reported by recently showing that actin-mediated PLT shape change and
505 phosphoinositide 3-kinase activity in response to FcγRIIA ligation in dependent on
506 intracellular calcium (28). The absence of ICU COVID-19 IgG-mediated PLT changes
507 could be also due to inactivation of calcium dependent cysteine protease calpain that
508 is crucial for the conformational changes in GP IIb/IIIa (34, 35). Another possible
509 explanation could be the inactivation of calcium dependent TMEM16F that bears
510 essential properties for membrane phospholipid scrambling and microparticle

511 generation (10). Future studies could explore the exact mechanisms by which
512 calcium contributes to procoagulant PLT formation in COVID-19.

513 COVID-19 antibody-induced procoagulant PLTs were significantly inhibited by
514 the use of inducers of adenylate cyclase (ADC) that are well known to cause
515 increased cAMP levels in PLTs (36). The protective effect of cAMP was further
516 demonstrated, as Iloprost, an already approved prostacyclin derivate and ADC,
517 efficiently prevented the formation of procoagulant PLTs in response to COVID-19
518 antibodies. Finally and of high clinical importance, Iloprost pretreatment of PLTs
519 markedly reduced COVID-19 IgG-induced clot formation on collagen suggesting that
520 cAMP inducers may have potential to prevent life threatening thromboembolic events
521 in COVID-19 antibody-mediated coagulopathy. Another minor finding from our
522 microfluidic system was that Iloprost, although significantly inhibited antibody-
523 mediated thrombus formation, did not affect the CD62p-single positive population.
524 Since Iloprost prevented clot formation, this finding might indicate that PS rather than
525 CD62p exposure on the PLT surface is pivotal to trigger the onset of thromboembolic
526 events.

527 Our study is subjected to some limitations. First, as an observational,
528 monocentric study, we cannot conclude that the reported associations between IgG
529 antibodies and changes in activation/apoptosis markers in COVID-19 are causal for
530 the thrombosis or specific for the disease. Second, we cannot exclude the possibility
531 of remaining residual confounding or unmeasured potential confounders in our
532 mechanistic studies. Third, the low number of patients does not enable a final and
533 robust statistical analysis to assess clinical outcomes in patients with increased
534 procoagulant PLTs. Nevertheless, data presented in this study may provide a
535 background for future studies to dissect mechanisms related to PLT activation that
536 are involved in the progression of COVID-19.

537 Taken together, our study shows that IgG antibodies from patients with severe
538 COVID-19 are able to stimulate FcγRIIA leading to the induction of procoagulant
539 PLTs with an increased ability of clot formation. These processes are dependent on
540 calcium and can be efficiently inhibited by cAMP inducers suggesting that ADC might
541 represent a potentially promising target to prevent thromboembolic complications in
542 COVID-19 disease.

543

544

545

546

547

548 **Author contributions**

549 J.Z., K.A., T.B. and P.R. designed the study. P.R. and H.H. were responsible for the
550 treatment of the patients. K.A. and H.H. collected and analyzed the clinical data. J.Z.,
551 K.A., H.J., L.P., A.S. and A.W. performed the experiments. J.Z., K.A., H.J., L.P., A.S.
552 and A.W. collected the data. J.Z., K.A., H.J., L.P., A.S., A.W., V.M., P.R. and T.B.
553 analyzed the data, interpreted the results and wrote the manuscript. All authors read
554 and approved the manuscript.

555

556 **Conflict of interest**

557 The authors have no conflict of Interests.

558

559 **Acknowledgements**

560 This work was supported by grants from the “Ministerium für Wissenschaft,
561 Forschung und Kunst Baden-Württemberg” to J.Z. and T.B. and from the Herzstiftung
562 to T.B. (BA5158/4 and TSG-Study) and TÜFF-Gleichstellungsförderung to K.A.
563 (2563-0-0). We thank Karoline Weich for her excellent technical support. The authors
564 thank Susanne Staub for editing the article as native English speaker.

565

566

567

568

569

570

571 **Figure legends**

572 **Fig. 1-ICU COVID-19 patient serum induced effects on PLTs during disease.**

573 **(A+B)** ICU COVID-19 (n=26) or ICU non-COVID-19 control (n=5) patient serum
574 induced changes in $\Delta\psi$ as well as PS externalization in wPLTs were analyzed by FC.
575 **(C+D)** Sera of 4 ICU COVID-19 patients were collected for up to 14 days during
576 hospitalization and analyzed for their ability to induce changes in $\Delta\psi$ as well as PS
577 externalization in wPLTs via FC. **(E)** Representative WB image of detected cleaved
578 caspase 3 (cleaved-) and procaspase 3 (pro-) levels in wPLTs that were incubated
579 with follow up sera of one ICU COVID-19 patient (indicated in **C+D**). **(F)**
580 Densitometric analysis of cleaved caspase 3/procaspase 3 ratios in wPLTs that were
581 incubated with follow up sera of ICU COVID-19 patients (n=4, [indicated in **C+D**])
582 normalized to control. α -Tubulin served as loading control. Data are presented as
583 mean \pm SEM of the measured fold increase compared to control. ns, not significant;
584 *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. The number of patient sera tested is
585 reported in each graph. Dot lines in **(A+B)** represent the calculated cutoffs
586 determined testing sera from healthy donors as mean of fold increase (FI)+2xSEM.
587 HC, healthy control; $\Delta\psi$, inner mitochondrial transmembrane potential; N, number of
588 HCs or patients; PS, phosphatidylserine.

589 **Fig. 2-ICU COVID-19 IgGs induce procoagulant PLTs and increased clot**
590 **formation.**

591 **Fig. 2.1. (A+C)** Representative FC plots of wPLTs' FSC vs. SSC properties after HC
592 or ICU COVID-19 IgG incubation. **(B+D)** Following HC or ICU COVID-19 IgG
593 incubation, CD42a positive gated wPLTs were analyzed for PS externalization and
594 expression of CD62p via Annexin V-FITC and CD62p-APC antibody staining,

595 respectively. **Fig. 2.1. (I-IV)** represent quantitative gate distribution of CD42a positive
596 events as indicated in **Fig. 2.1. (B+D)**. Data are shown as percentage \pm SEM of
597 Annexin V-FITC and or CD62p-APC positive labeled wPLTs after incubation with HC
598 (n=8), ICU non-COVID-19 (n=5) or ICU COVID-19 IgG (n=10). ns, not significant;
599 *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. The number of patients and healthy
600 donors tested is reported in each graph. HC, healthy control; N, number of HCs or
601 patients; PS, phosphatidylserine.

602 **Fig. 3-ICU COVID-19 IgG cause increased clot formation on collagen.**

603 **(A)** PRP from healthy individuals with the blood group O was incubated with HC
604 (n=6), ICU non-COVID-19 control (n=3) or ICU COVID-19 IgG (n=10), labelled with
605 FITC conjugated calcein and perfused through microfluidic channels at a shear rate
606 of 1500⁻¹ (60 dyne) for 5 min after reconstitution into autologous whole blood. Images
607 were aquired at x20 magnification in the fluorescent (upper panel) as well as in the
608 BF channel (lower panel). Scale bar 50 μ m. **(B)** Mean percentage of surface area
609 covered (mean % SAC) \pm SEM by thrombus in the presence of HC (n=6), ICU non-
610 COVID-19control (n=3) and ICU COVID-19 (n=10) IgG after 5 min perfusion time. ns,
611 not significant; *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. The number of
612 patients and healthy donors tested is reported in each graph. HC, healthy control; N,
613 number of HCs or patients.

614 **Fig. 4-ICU COVID-19 IgG induced formation of procoagulant PLTs is Fc γ RIIA**
615 **dependent.**

616 **Fig. 4.1. (A)** ICU COVID-19 patient serum (n=10) induced changes of $\Delta\psi$ in wPLTs
617 were analyzed in the presence or absence of moAb IV.3 via FC. Data are presented
618 as mean \pm SEM of the measured fold increase compared to control. **(B+C)**

619 Representative WB image of detected cleaved caspase 3 (cleaved-) and procaspase
620 3 (pro-) levels in wPLTs that were incubated with ICU COVID-19 IgG (n=4) in the
621 presence or absence of moAb IV.3. α -Tubulin served as loading control. **(C)**
622 Densitometric analysis of cleaved caspase 3/procaspase 3 ratios from immunoblots
623 as indicated in **(B, n=4)** normalized to control. **Fig. 4.2. (A+C)** Representative FC
624 plots of wPLTs' FSC vs. SSC after ICU COVID-19 IgG incubation in IV.3 pretreated
625 wPLTs. **(B+D)** Gate distribution of CD42a positive PS (Annexin V-FITC) externalizing
626 and CD62p (CD62p-APC) expressing wPLTs after ICU COVID-19 IgG incubation in
627 isotype control or IV.3 pretreated wPLTs. **Fig. 4.2. (I-IV)** shows quantitative gate
628 distributions of wPLTs with or without IV.3 pretreatment, after ICU COVID-19 IgG
629 incubation as shown in **Fig. 4.2. (B+D)**. Data are presented as percentage \pm SEM of
630 Annexin V-FITC and or CD62p-APC positive labeled wPLTs after incubation with HC
631 (n=3) or ICU COVID-19 IgG (n=8) in the presence or absence of moAb IV.3. ns, not
632 significant; *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. The number of patients
633 and healthy donors tested is reported in each graph. HC, healthy control; N, number
634 of HCs or patients; PS, phosphatidylserine.

635 **Fig. 5-Fc γ RIIA inhibition prevents ICU COVID-19 IgG induced increased clot**
636 **formation.**

637 **(A)** PRP from healthy individuals with the blood group O was incubated with HC
638 (n=2) or ICU COVID-19 IgG (n=3 patients) in the presence of moAb IV.3 or isotype
639 control (moAb) and perfused through microfluidic channels at a shear rate of 1500⁻¹
640 (60 dyne) for 5 min. Images were acquired at x20 magnification in fluorescent (upper
641 panel) as well as in the BF channel (lower panel). Scale bar 50 μ m. **(B)** mean %
642 SAC \pm SEM induced by HC (n=2) or ICU COVID-19 IgG (n=3) in the presence or
643 absence of moAb IV.3 or isotype control (moAb). ns, not significant; *p<0.05,

644 **p<0.01, ***p<0.001 and ****p<0.0001. The number of patients and healthy donors
645 tested is reported in each graph. moAb, monoclonal isotype control; HC, healthy
646 control; N, number of HCs or patients

647 **Fig. 6-ICU COVID-19 IgG induced formation of procoagulant PLTs is dependent**
648 **on extracellular calcium.**

649 **Fig. 6.1. (A)** FC assessment of ICU COVID-19 IgG (n=5) induced changes of $\Delta\psi$ in
650 wPLTs that were pretreated with EGTA (1 mM) or vehicle. Data are presented as
651 mean \pm SEM of the measured fold increase compared to control. **(B+C)**

652 Representative WB image of detected cleaved caspase 3 (cleaved-) and procaspase
653 3 (pro-) levels in EGTA (1 mM) vehicle pretreated wPLTs that were incubated with
654 ICU COVID-19 IgG (n=6), respectively. α -Tubulin served as loading control. **(C)**

655 Densitometric analysis of immunoblots indicated in **(B)** for cleaved caspase
656 3/procaspase 3 ratios from WB data as indicated in **(B, [n=5])** normalized to control.

657 **Fig. 6.2. (A+C)** Representative FC plots of wPLTs' FSC vs. SSC after ICU COVID-
658 19 IgG incubation in EGTA (1mM) or vehicle pretreated wPLTs. **(B+D)** Gate
659 distribution of CD42a positive PS (Annexin V-FITC) externalizing and CD62p
660 (CD62p-APC) expressing wPLTs after ICU COVID-19 IgG incubation in EGTA (1mM)

661 or vehicle pretreated wPLTs. **Fig. 6.2. (B+D)** Gate distribution of CD42a positive PS
662 (Lactadherin-FITC) externalizing and CD62p (CD62p-APC) expressing wPLTs after
663 ICU COVID-19 IgG incubation in EGTA (1 mM) or vehicle containing wPLTs. **Fig.**

664 **6.2. (I-IV)** shows quantitative gate distribution of wPLTs after incubation with ICU
665 COVID-19 IgG. Data are presented as percentage \pm SEM of Lactadherin-FITC or
666 CD62p-APC positive labeled wPLTs after incubation with HC (n=3) or ICU COVID-19
667 IgG (n=9) in vehicle or EGTA (1 mM) pretreated wPLTs. ns, not significant; *p<0.05,

668 **p<0.01, ***p<0.001 and ****p<0.0001. The number of patients and healthy donors

669 tested is reported in each graph. HC, healthy control; N, number of HCs or patients;
670 PS, phosphatidylserine.

671 **Fig. 7-Depletion of intracellular calcium abrogates ICU COVID-19 IgG induced**
672 **procoagulant PLT formation.**

673 **Fig. 7.1 (A)** ICU COVID-19 IgG (n=9) induced changes of $\Delta\psi$ in wPLTs were
674 analyzed in the presence or absence of the intracellular calcium chelator BAPTA (20
675 μM). **(B)** Representative WB image of cleaved caspase 3 (cleaved-) and procaspase
676 3 (pro-) were detected with anti-caspase 3 antibody in wPLTs that were incubated
677 with ICU COVID-19 IgG in BAPTA (20 μM) or vehicle pretreated wPLTs. α -Tubulin
678 served as loading control. **(C)** Densitometric analysis of cleaved caspase
679 3/procaspase 3 ratios from immunoblots (indicated in **B**, [n=4]) normalized to control.

680 **Fig. 7.2. (A+C)** FC plots of wPLTs' FSC and. SSC after ICU COVID-19 IgG
681 incubation in vehicle or BAPTA (20 μM) preloaded wPLTs. **(B+D)** FC plots of CD42a
682 positive gated wPLTs that were incubated with ICU COVID-19 IgG in vehicle or in
683 BAPTA (20 μM) preloaded wPLTs. **Fig. 7.2.(I-IV)** quantitative gate distribution of
684 CD42a positive wPLTs based on the gate settings shown in **Fig. 7.2. (B+D)**. Data are
685 shown as percentage \pm SEM of Lactadherin-FITC and or CD62p-APC positive labeled
686 wPLTs after HC (n=3) or ICU COVID-19 IgG (n=10) incubation in normal or BAPTA
687 (20 μM) preloaded wPLTs. Ns, not significant; *p<0.05, **p<0.01, ***p<0.001 and
688 ****p<0.0001. The number of patients and healthy donors tested is reported in each
689 graph. HC, healthy control; N, number of HCs or patients, PS; phosphatidylserine.

690 **Fig. 8-Forskolin protects ICU COVID-19 IgG induced procoagulant PLT**
691 **formation.**

692 **Fig. 8.1. (A)** FC analysis of ICU COVID-19 IgG (n=5 patients) induced changes in $\Delta\psi$
693 of wPLTs, that were pretreated with vehicle or the ADC inductor Forskolin (2.25 μ M)
694 for 30 min at 37°C. Data are presented as mean \pm SEM of the measured fold increase
695 compared to control. **(B)** Representative WB image of cleaved caspase 3 (cleaved-)
696 and procaspase 3 (pro-) levels detected in wPLTs that were incubated with ICU
697 COVID-19 IgG in vehicle or Forskolin (2.25 μ M) pretreated wPLTs. α -Tubulin served
698 as loading control. **(C)** Densitometric assessed ratios of cleaved caspase
699 3/procaspase 3 (as indicated in **B** [n=6]) normalized to control. **Fig. 8.2. (A+C)** FC
700 plots of wPLTs' FSC vs. SSC after ICU COVID-19 IgG incubation in vehicle or
701 Forskolin (2.25 μ M) pretreated wPLTs. **(B+D)** Gate distribution of CD42a positive
702 wPLTs that were incubated with ICU COVID-19 IgG vehicle or Forskolin (2.25 μ M)
703 pretreated wPLTs. **Fig. 8.2. (I-IV)** Quantitative distribution of CD42a positive wPLTs
704 based on the gate settings shown in **Fig. 8.2. (B+D)**. Data are shown as percentage
705 \pm SEM of Annexin V-FITC and or CD62p-APC positive labeled wPLTs that were
706 incubated with IgGs from HC (n=3) or ICU COVID-19 IgG (n=6) in vehicle or
707 Forskolin (2.25 μ M) pretreated wPLTs. ns, not significant; *p<0.05, **p<0.01,
708 ***p<0.001 and ****p<0.0001. The number of patients and healthy donors tested is
709 reported in each graph. HC, healthy control; N, number of HCs or patients; PS,
710 phosphatidylserine.

711

712 **Fig. 9-cAMP elevation via Iloprost prevents ICU COVID-19 IgG induced**
713 **procoagulant PLTs.**

714 **Fig. 9.1. (A)** Changes in $\Delta\psi$ depolarization induced by ICU COVID-19 IgG (n=8
715 patients) were analyzed in vehicle or Iloprost (20 nM) pretreated wPLTs via FC. Data

716 are presented as mean \pm SEM of the measured fold increase compared to control. **(B)**
717 Representative WB image of detected caspase 3 (cleaved-) and procaspase 3 (pro-)
718 levels in wPLTs that were pretreated with vehicle or Iloprost (20 nM) prior to ICU
719 COVID-19 IgG incubation. α -Tubulin served as loading control. **(C)** Densitometric
720 analysis of cleaved caspase 3/procaspase 3 ratios from the WB data (indicated in **B**,
721 [n=7]) normalized to control. **Fig. 9.2. (A+C)** FC detected changes in wPLTs' FSC vs.
722 SSC properties after ICU COVID-19 IgG incubation in vehicle or Iloprost (20 nM)
723 pretreated wPLTs. **Fig. 9.2. (B+D) (E+G)** Gate distribution of CD42a positive vehicle
724 or Iloprost (20 nM) pretreated wPLTs that were incubated with ICU COVID-19 IgG.
725 **Fig. 9.2. (I-IV)** Quantitative distribution of the CD42a positive wPLT population based
726 on the gate settings shown in **Fig. 9.2. (B+D)**. Data are shown as percentage \pm SEM
727 of Annexin V-FITC and or CD62p-APC positive labeled wPLTs that were incubated
728 with HC (n=3) or ICU COVID-19 IgG (n=6) in vehicle or Iloprost (20 nM) pretreated
729 wPLTs. ns, not significant; *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. The
730 number of patients and healthy donors tested is reported in each graph. HC, healthy
731 control; N, number of HCs or patients; PS, phosphatidylserine.

732 **Fig. 10-Iloprost inhibits ICU COVID-19 IgG induced increased clot formation.**

733 **(A)** PRP from healthy individuals with the blood group O was incubated with HC
734 (n=3) or ICU COVID-19 IgG (n=5) in the presence of vehicle or Iloprost (20 nM). After
735 reconstitution into autologous whole blood, samples were perfused through
736 microfluidic channels at a shear rate of 1500⁻¹ (60 dyne) for 5 min. Pictures were
737 acquired at x20 magnification in fluorescent (upper panel) as well as in the BF channel
738 (lower panel). Scale bar 50 μ m. **(B)** Mean % SAC \pm SEM induced by HC (n=3) or ICU
739 COVID-19 IgG (n=5) in the presence of vehicle or Iloprost (20 nM). ns, not significant;
740 *p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001. The number of patients and healthy

741 donors tested is reported in each graph. HC, healthy control; N, number of HCs or
742 patients; PS, phosphatidylserine.

743

744

745 **References:**

746

- 747 1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of
748 adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet*.
749 2020;395(10229):1054-62.
- 750 2. Hanff TC, Mohareb AM, Giri J, Cohen JB, Chirinos JA. Thrombosis in COVID-19. *Am J Hematol*.
751 2020;95(12):1578-89.
- 752 3. Iba T, Levy JH, Levi M, Connors JM, Thachil J. Coagulopathy of Coronavirus Disease 2019. *Crit*
753 *Care Med*. 2020;48(9):1358-64.
- 754 4. Henry BM, Vikse J, Benoit S, Favaloro EJ, Lippi G. Hyperinflammation and derangement of
755 renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected
756 hypercoagulopathy and microvascular immunothrombosis. *Clin Chim Acta*. 2020;507:167-73.
- 757 5. Hottz ED, Azevedo-Quintanilha IG, Palhinha L, Teixeira L, Barreto EA, Pao CRR, et al. Platelet
758 activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients
759 with severe COVID-19. *Blood*. 2020;136(11):1330-41.
- 760 6. Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben C, et al. Platelet gene
761 expression and function in patients with COVID-19. *Blood*. 2020;136(11):1317-29.
- 762 7. de Witt SM, Verdoold R, Cosemans JM, Heemskerk JW. Insights into platelet-based control of
763 coagulation. *Thromb Res*. 2014;133 Suppl 2:S139-48.
- 764 8. Swieringa F, Spronk HMH, Heemskerk JWM, van der Meijden PEJ. Integrating platelet and
765 coagulation activation in fibrin clot formation. *Res Pract Thromb Haemost*. 2018;2(3):450-60.
- 766 9. Agbani EO, Poole AW. Procoagulant platelets: generation, function, and therapeutic targeting
767 in thrombosis. *Blood*. 2017;130(20):2171-9.
- 768 10. Reddy EC, Rand ML. Procoagulant Phosphatidylserine-Exposing Platelets in vitro and in vivo.
769 *Front Cardiovasc Med*. 2020;7:15.
- 770 11. Hua VM, Chen VM. Procoagulant platelets and the pathways leading to cell death. *Semin*
771 *Thromb Hemost*. 2015;41(4):405-12.
- 772 12. Greinacher A, Michels I, Kiefel V, Mueller-Eckhardt C. A rapid and sensitive test for diagnosing
773 heparin-associated thrombocytopenia. *Thromb Haemost*. 1991;66(6):734-6.
- 774 13. Marini I, Zlamal J, Faul C, Holzer U, Hammer S, Pelzl L, et al. Autoantibody-mediated
775 desialylation impairs human thrombopoiesis and platelet life span. *Haematologica*. 2019.
- 776 14. Mangin PH, Gardiner EE, Nesbitt WS, Kerrigan SW, Korin N, Lam WA, et al. In vitro flow based
777 systems to study platelet function and thrombus formation: Recommendations for standardization:
778 Communication from the SSC on Biorheology of the ISTH. *J Thromb Haemost*. 2020;18(3):748-52.
- 779 15. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with
780 2019 novel coronavirus in Wuhan, China. *Lancet*. 2020;395(10223):497-506.
- 781 16. Mammadova-Bach E, Nagy M, Heemskerk JWM, Nieswandt B, Braun A. Store-operated
782 calcium entry in thrombosis and thrombo-inflammation. *Cell Calcium*. 2019;77:39-48.
- 783 17. Nagy Z, Smolenski A. Cyclic nucleotide-dependent inhibitory signaling interweaves with
784 activating pathways to determine platelet responses. *Res Pract Thromb Haemost*. 2018;2(3):558-71.
- 785 18. Zhao L, Liu J, He C, Yan R, Zhou K, Cui Q, et al. Protein kinase A determines platelet life span
786 and survival by regulating apoptosis. *J Clin Invest*. 2017;127(12):4338-51.

- 787 19. Fisch A, Michael-Hepp J, Meyer J, Darius H. Synergistic interaction of adenylate cyclase
788 activators and nitric oxide donor SIN-1 on platelet cyclic AMP. *Eur J Pharmacol.* 1995;289(3):455-61.
- 789 20. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor
790 prognosis in patients with novel coronavirus pneumonia. *J Thromb Haemost.* 2020;18(4):844-7.
- 791 21. Roka-Moia Y, Walk R, Palomares DE, Ammann KR, Dimasi A, Italiano JE, et al. Platelet
792 Activation via Shear Stress Exposure Induces a Differing Pattern of Biomarkers of Activation versus
793 Biochemical Agonists. *Thromb Haemost.* 2020;120(5):776-92.
- 794 22. Shcherbina A, Remold-O'Donnell E. Role of caspase in a subset of human platelet activation
795 responses. *Blood.* 1999;93(12):4222-31.
- 796 23. Bonomini M, Dottori S, Amoroso L, Arduini A, Sirolli V. Increased platelet phosphatidylserine
797 exposure and caspase activation in chronic uremia. *J Thromb Haemost.* 2004;2(8):1275-81.
- 798 24. Chong BH, Fawaz I, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia:
799 mechanism of interaction of the heparin-dependent antibody with platelets. *Br J Haematol.*
800 1989;73(2):235-40.
- 801 25. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia (HIT) and its
802 differentiation from non-HIT thrombocytopenia. *Thromb Haemost.* 2016;116(5):813-22.
- 803 26. Rink TJ, Sage SO. Calcium signaling in human platelets. *Annu Rev Physiol.* 1990;52:431-49.
- 804 27. Rayes J, Watson SP, Nieswandt B. Functional significance of the platelet immune receptors
805 GPVI and CLEC-2. *J Clin Invest.* 2019;129(1):12-23.
- 806 28. Barkalow KL, Falet H, Italiano JE, Jr., van Vugt A, Carpenter CL, Schreiber AD, et al. Role for
807 phosphoinositide 3-kinase in Fc gamma RIIA-induced platelet shape change. *Am J Physiol Cell Physiol.*
808 2003;285(4):C797-805.
- 809 29. Kunzelmann-Marche C, Freyssinet JM, Martinez MC. Regulation of phosphatidylserine
810 transbilayer redistribution by store-operated Ca²⁺ entry: role of actin cytoskeleton. *J Biol Chem.*
811 2001;276(7):5134-9.
- 812 30. Bergmeier W, Oh-Hora M, McCarl CA, Roden RC, Bray PF, Feske S. R93W mutation in Orai1
813 causes impaired calcium influx in platelets. *Blood.* 2009;113(3):675-8.
- 814 31. Heemskerk JW, Vuist WM, Feijge MA, Reutelingsperger CP, Lindhout T. Collagen but not
815 fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity
816 of adherent platelets: evidence for regulation by protein tyrosine kinase-dependent Ca²⁺ responses.
817 *Blood.* 1997;90(7):2615-25.
- 818 32. Tomiyama Y, Kosugi S. Autoantigenic epitopes on platelet glycoproteins. *Int J Hematol.*
819 2005;81(2):100-5.
- 820 33. Schoenwaelder SM, Yuan Y, Josefsson EC, White MJ, Yao Y, Mason KD, et al. Two distinct
821 pathways regulate platelet phosphatidylserine exposure and procoagulant function. *Blood.*
822 2009;114(3):663-6.
- 823 34. Mattheij NJ, Gilio K, van Kruchten R, Jobe SM, Wieschhaus AJ, Chishti AH, et al. Dual
824 mechanism of integrin alphaIIb beta3 closure in procoagulant platelets. *J Biol Chem.*
825 2013;288(19):13325-36.
- 826 35. Kulkarni S, Jackson SP. Platelet factor XIII and calpain negatively regulate integrin
827 alphaIIb beta3 adhesive function and thrombus growth. *J Biol Chem.* 2004;279(29):30697-706.
- 828 36. Smolenski A. Novel roles of cAMP/cGMP-dependent signaling in platelets. *J Thromb*
829 *Haemost.* 2012;10(2):167-76.
- 830

Figure 1




Figure 2.1.




Figure 2.1.





Figure 3

A



B






Figure 4.1.

A



B



C




Figure 4.2.




Figure 4.2. I-IV





Figure 5

A



B




Figure 6.1.




Figure 6.2.




Figure 6.2. I-IV




Figure 7.1.




Figure 7.2.




Figure 7.2. I-IV






Figure 8.1.

A



B



C




Figure 8.2.




Figure 8.2. I-IV




Figure 9.1.




Figure 9.2.




Figure 9.2. I-IV





Figure 10

A



B

